Science and technology company Battelle disclosed on Monday that Dr Wayne A I Frederick, current president of Howard University and the Charles R Drew Professor of Surgery, has been elected to the Battelle board of directors.
Dr Frederick will initially serve in an advisory role and will become a full voting member on the company's board in 2022.
Following post-doctoral research and surgical oncology fellowships at the University of Texas MD Anderson Cancer Center, Dr Frederick began his academic career as associate director of the cancer center at the University of Connecticut. He was appointed the seventeenth president of Howard University in 2014 and has been responsible for advancing the university's commitment to student opportunity, academic innovation, public service, and fiscal stability. He previously served as provost and chief academic officer.
Currently, Dr Frederick serves on the board of directors for the Federal Reserve Bank of Richmond and Humana Inc.
Headquartered in Columbus, Ohio and founded in 1929, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Battelle also supports science, technology, engineering and mathematics (STEM) education.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients